{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:54:45Z","timestamp":1790898885200,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016259","name":"Viatris Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Basic to Translational Science"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jacbts.2026.101664","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T20:56:23Z","timestamp":1787604983000},"page":"101664","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Rates of Lipoprotein(a) Oxidation Accelerate at Elevated Levels and Attenuate With Atorvastatin Active Metabolites Compared With Other Statins"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0913-2865","authenticated-orcid":false,"given":"Samuel C.R.","family":"Sherratt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Libby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1278-6245","authenticated-orcid":false,"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5483-1852","authenticated-orcid":false,"given":"R. Preston","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacbts.2026.101664_bib1","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacbts.2026.101664_bib2","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"404","author":"Nordestgaard","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jacbts.2026.101664_bib3","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacbts.2026.101664_bib4","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacbts.2026.101664_bib5","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacbts.2026.101664_bib6","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCGENETICS.113.000400","article-title":"Lipoprotein(a) levels, genotype, and incident aortic valve stenosis","volume":"7","author":"Arsenault","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.jacbts.2026.101664_bib7","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.124.071269","volume":"151","author":"Steg","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2026.101664_bib8","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41569-023-00937-4","article-title":"Oxidized phospholipids in cardiovascular disease","volume":"21","author":"Tsimikas","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacbts.2026.101664_bib9","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1001\/jamacardio.2022.0987","article-title":"Lipoprotein(a) and its significance in cardiovascular disease: a review","volume":"7","author":"Duarte Lau","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacbts.2026.101664_bib10","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1093\/cvr\/cvaf144","article-title":"Eicosapentaenoic acid (EPA) limits the more rapid oxidation of lipoprotein(a) [Lp(a)] compared with other ApoB particles","volume":"121","author":"Sherratt","year":"2025","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacbts.2026.101664_bib11","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2026.101664_bib12","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacbts.2026.101664_bib13","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jacbts.2026.101664_bib14","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1186\/s12872-022-02932-y","article-title":"Effect of an increase in Lp(a) following statin therapy on cardiovascular prognosis in secondary prevention population of coronary artery disease","volume":"22","author":"Zhu","year":"2022","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jacbts.2026.101664_bib15","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/eurjpc\/zwab171","article-title":"Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis","volume":"29","author":"de Boer","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacbts.2026.101664_bib16","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0090-9556(24)15242-7","article-title":"Metabolism and excretion of atorvastatin in rats and dogs","volume":"27","author":"Black","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jacbts.2026.101664_bib17","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.2165\/00003495-200161120-00012","article-title":"Atorvastatin","volume":"61","author":"Malhotra","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.jacbts.2026.101664_bib18","doi-asserted-by":"crossref","first-page":"11F","DOI":"10.1016\/j.amjcard.2005.06.008","article-title":"Intermolecular differences for HMG-CoA reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions","volume":"96","author":"Mason","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacbts.2026.101664_bib19","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/FJC.0b013e318294998d","article-title":"Atorvastatin active metabolite inhibits oxidative modification of small dense low-density lipoprotein","volume":"62","author":"Jacob","year":"2013","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jacbts.2026.101664_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamem.2020.183254","article-title":"Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro","volume":"1862","author":"Sherratt","year":"2020","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"10.1016\/j.jacbts.2026.101664_bib21","doi-asserted-by":"crossref","first-page":"9337","DOI":"10.1074\/jbc.M513000200","article-title":"Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism","volume":"281","author":"Mason","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacbts.2026.101664_bib22","doi-asserted-by":"crossref","first-page":"5036","DOI":"10.3390\/molecules27155036","article-title":"Why Ortho- and para-hydroxy metabolites can scavenge free radicals that the parent atorvastatin cannot? Important pharmacologic insight from quantum chemistry","volume":"27","author":"B\u00e2ldea","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.jacbts.2026.101664_bib23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.amjcard.2005.06.008","article-title":"Intermolecular differences of 3-Hydroxy-3-Methylglutaryl coenzyme A reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions","volume":"96","author":"Mason","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacbts.2026.101664_bib24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1089\/ars.2009.2733","article-title":"Oxidized LDL: diversity, patterns of recognition, and pathophysiology","volume":"13","author":"Levitan","year":"2010","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.jacbts.2026.101664_bib25","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1161\/CIRCRESAHA.108.190116","article-title":"Mediation of electronegative low-density lipoprotein signaling by LOX-1","volume":"104","author":"Lu","year":"2009","journal-title":"Circ Res"},{"key":"10.1016\/j.jacbts.2026.101664_bib26","doi-asserted-by":"crossref","first-page":"39380","DOI":"10.1074\/jbc.M507587200","article-title":"Lipid peroxidation induces cholesterol domain formation in model membranes","volume":"280","author":"Jacob","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacbts.2026.101664_bib27","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jacbts.2026.101664_bib28","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jacc.2022.01.014","article-title":"Lipoprotein(a) cholesterol masquerading as low-density lipoprotein cholesterol","volume":"79","author":"Par\u00e9","year":"2022","journal-title":"JACC"},{"key":"10.1016\/j.jacbts.2026.101664_bib29","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1161\/01.CIR.103.15.1955","article-title":"Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes","volume":"103","author":"Ehara","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2026.101664_bib30","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/j.jacc.2004.08.029","article-title":"Serum levels of TBARS predict cardiovascular events in patients with stable coronary artery disease: a longitudinal analysis of the PREVENT study","volume":"44","author":"Walter","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacbts.2026.101664_bib31","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.jacc.2007.11.051","article-title":"Circulating lipid hydroperoxides predict cardiovascular events in patients with stable coronary artery disease: the PREVENT study","volume":"51","author":"Walter","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacbts.2026.101664_bib32","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacbts.2026.101664_bib33","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacbts.2026.101664_bib34","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O\u2019Donoghue","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacbts.2026.101664_bib35","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.2337\/dc20-2842","article-title":"Relation of lipoprotein(a) levels to incident type 2 diabetes and modification by alirocumab treatment","volume":"44","author":"Schwartz","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacbts.2026.101664_bib36","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.jacc.2024.02.016","article-title":"Lipoprotein(a) blood levels and cardiovascular risk reduction with icosapent ethyl","volume":"83","author":"Szarek","year":"2024","journal-title":"J Am Coll Cardiol"}],"container-title":["JACC: Basic to Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452302X26001877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452302X26001877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:13:35Z","timestamp":1790896415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452302X26001877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2452302X26001877"],"URL":"https:\/\/doi.org\/10.1016\/j.jacbts.2026.101664","relation":{},"ISSN":["2452-302X"],"issn-type":[{"value":"2452-302X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rates of Lipoprotein(a) Oxidation Accelerate at Elevated Levels and Attenuate With Atorvastatin Active Metabolites Compared With Other Statins","name":"articletitle","label":"Article Title"},{"value":"JACC: Basic to Translational Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacbts.2026.101664","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"101664"}}